Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects positive sentiment, with strong financial performance, increased revenue guidance, and optimistic growth in various segments like thrombectomy and embolization. The Q&A highlights favorable reception of clinical data and minimal impact from tariffs. However, conservative Q4 guidance and lack of clarity on FDA approval specifics slightly temper expectations. Overall, the company's strategic initiatives and market position suggest a positive outlook for stock price movement.
Key Financial Performance
Total Revenue $354.7 million, representing underlying year-over-year growth of 17.8% on a reported basis and 16.9% on a constant currency basis. The growth reflects broad-based execution against strategy and significant progress in enhancing competitive technological and market positioning.
Total U.S. Revenue $275 million, an increase of 21.5% compared to the third quarter of 2024. Growth driven by thrombectomy sales and embolization/access revenue.
U.S. Thrombectomy Sales $192 million, increased 18.5% year-over-year. Growth attributed to clinical benefits and competitive strength of CAVT technology alongside enhanced commercial focus.
U.S. Embolization and Access Revenue $83 million, increased 29.2% year-over-year. Growth exceeded expectations due to a dedicated peripheral embolization sales team and investment in innovation and new product introductions.
Total International Revenue $79.7 million, increased 6.6% year-over-year or 3% in constant currency. Growth offset by China growth comp headwinds but supported by portfolio and geographic strength.
Gross Margin 67.8%, expanded 130 basis points over the prior year period. Growth driven by favorable regional mix, product mix, and productivity improvements.
Operating Income $48.8 million or 13.8% of revenue, compared to $40.3 million or 13.4% of revenue in the same period last year. Growth reflects the impact of embolization sales force build-out.
Adjusted EBITDA $66.7 million or 18.8% of total revenue, compared to $56.7 million or 18.8% in the third quarter last year. Growth supported by profitability and operational leverage.
Cash, Cash Equivalents, and Marketable Securities $470.3 million, an increase of $45.7 million sequentially. Growth includes improving working capital ratios and strong profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA clearance for Lightning Bolt 16 and Lightning Flash 3.0: These products enhance the CAVT portfolio, targeting over 800,000 U.S. patients with VTE and arterial clot issues.
Ruby XL launch: Successful launch contributed to 21.2% sequential growth in embolization revenue.
Thunderbolt submission: Responses to FDA questions submitted, aiming to introduce CAVT to the neurovascular field.
U.S. revenue growth: Total U.S. revenue increased by 21.5% year-over-year, driven by thrombectomy and embolization sales.
International revenue growth: International revenue grew by 6.6% year-over-year, overcoming China growth headwinds.
Gross margin improvement: Gross margin increased to 67.8%, with a target of over 70% by 2026.
Sales team expansion: Added 50+ peripheral embolization sales reps, driving growth in embolization revenue.
STORM-PE trial results: Proved CAVT superior to standard care for PE, with significant long-term functional improvements.
Patent defense: Secured a legal victory affirming the validity of CAVT-related patents.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company is in the process of addressing final questions and clarifications from the FDA regarding the Thunderbolt 510(k) review process. This regulatory hurdle could delay the introduction of CAVT to the neurovascular field.
Market Trends in Neurovascular Business: The U.S. stroke market showed a slight decline in the third quarter, which could impact the growth and performance of the company's neurovascular business.
China Growth Headwinds: The company continues to face growth headwinds in China, which could affect its international revenue performance.
Operational Costs: The company has made significant investments in expanding its sales teams and product development, which has increased SG&A expenses. This could pressure operating margins if revenue growth does not keep pace.
Competitive Pressures: The company is actively defending its patents and intellectual property for CAVT technology, indicating ongoing competitive pressures in the market.
Economic Uncertainties: The company’s financial performance could be impacted by broader economic uncertainties, as implied by the cautionary statements regarding forward-looking projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its revenue guidance for 2025 to $1.375 billion to $1.380 billion, reflecting strong business trends and market performance.
U.S. Thrombectomy Growth: The company reiterates 20% to 21% year-over-year growth for 2025 in the U.S. thrombectomy segment.
Gross Margin Expansion: The company expects to achieve a gross margin profile of over 70% by the end of 2026, with operating margin expansion outpacing gross margin expansion in the foreseeable future.
Peripheral Embolization Business: The company anticipates sustainable growth in the U.S. embolization franchise, supported by a dedicated sales team and new product launches like Ruby XL.
Thunderbolt Product Launch: The company is optimistic about introducing Thunderbolt to the neurovascular field, which is expected to catalyze growth in the stroke market.
STORM-PE Trial Impact: The STORM-PE trial results are expected to act as a major catalyst in positively impacting the treatment of pulmonary embolism (PE) and increasing the number of patients receiving intervention with CAVT technology.
Market Trends in Neurovascular Business: The company is optimistic about market growth driven by innovation, particularly with the anticipated introduction of Thunderbolt.
Long-Term Strategy: The company remains confident in its long-term strategy focused on innovation, data generation, and team investment to support durable, profitable growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company progressing with the FDA approval process for Thunderbolt, and what are the expectations for its market launch?
A:The company is optimistic about the FDA approval process for Thunderbolt, noting that it is a brand-new product and not just seeking a new indication. The process is thorough and comparable to previous experiences with new products. The company is ready to launch the product once approved but refrains from providing specific details until clearance is received.
Q:What is the impact of the STORM-PE secondaries on the market and the company's position?
A:The STORM-PE data has been positively received by the medical community, with strong safety and functional outcomes. This has led to increased interest and adoption among interventionalists and non-interventionalists, with institutions updating protocols to provide more patient access to care.
Q:How is the company addressing margin improvements and the impact of tariffs?
A:The company is seeing favorable trends in regional and product mix, as well as operational improvements. New products like Thunderbolt and the newest coil are accretive to margins. Tariff impacts are minimal and have already been absorbed in the current trends.
Q:What are the trends in the U.S. thrombectomy market, and how does the company view its growth potential?
A:The U.S. thrombectomy market has seen deceleration in stroke but strong growth in venous and arterial segments. The company has maintained its market share and expects growth to stabilize and accelerate with new technology and market dynamics.
Q:What drove the strong performance in Embo Access in Q3, and what are the expectations going forward?
A:The strong performance was driven by a dedicated team and the launch of new products like Ruby XL and Swift. The company expects Embo Access to continue outpacing thrombectomy and to be a significant growth driver in the future.
Q:Why does the guidance imply a deceleration in Q4, and what are the expectations for 2025 growth?
A:The guidance reflects a conservative approach, with no specific concerns highlighted. The company remains optimistic about its business and expects strong growth momentum into 2025, despite a 4% headwind from China.
Q:What is the outlook for international sales, particularly in China?
A:China headwinds are expected to wane by early next year, with minimal impact anticipated in 2025. Other international regions are growing in double digits, with thrombectomy showing mid-teen growth.
Q:What is the potential impact of STORM-PE on clinical practice and procedure adoption?
A:STORM-PE has the potential to change clinical practice, with hospitals updating protocols and non-interventionalists leading efforts to adopt thrombectomy for PE cases. The data has been well-received, and the company expects increased adoption and guideline updates over time.
Q:What are the company's expectations for Lightning Flash 3.0?
A:Lightning Flash 3.0 is expected to improve case times and safety profiles further, enhancing the performance of the company's thrombectomy products.
Q:What are the trends in the DVT segment, and how is the company addressing health economics?
A:The DVT segment is growing consistently, driven by the adoption of Flash 2.0 and the positive impact of STORM-PE. The company continues to focus on health economics and market access data to support adoption.
Q:What is the company's view on the growth of PERT teams and their impact on the market?
A:The company sees significant energy and focus around pulmonary embolism patients, with more hospitals forming PERT teams and adopting newer technologies. This is expected to drive market growth over the next few years.
Q:What are the key drivers of growth in the embolization market?
A:Growth is driven by the focus of a dedicated team, the performance of the company's coils, and the increasing number of MMA procedures. The company expects embolization to remain a significant growth area.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the FDA's specific requirements for Thunderbolt approval, stating only that they have answered all questions received so far and that the process is ongoing. Additionally, they did not provide clear reasons for the conservative Q4 guidance, emphasizing a cautious approach without detailing specific concerns.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAVT embolization
Dr
FDA
STORM PE
TCT
VIVA
ability
addition
case
coil
community
date
decision
detail
embolization franchise
embolization sale
endpoint
integration
introduction
investment
market positioning
neuro
outcome
patent
portfolio
procedure
process
risk PE
safety profile
sale embolization
sale force
shift
significance
standard care
strength
stroke market
time
transition
treatment
trial CAVT
week
wind
PEN Transcript
Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-3
Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reflects positive sentiment, with strong financial performance, increased revenue guidance, and optimistic growth in various segments like thrombectomy and embolization. The Q&A highlights favorable reception of clinical data and minimal impact from tariffs. However, conservative Q4 guidance and lack of clarity on FDA approval specifics slightly temper expectations. Overall, the company's strategic initiatives and market position suggest a positive outlook for stock price movement.
Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript
Neutral10-27
PEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
